Research and laboratory use only. Not for human consumption.
Hexarelin
Hexarelin is a synthetic six-residue growth hormone-releasing peptide developed as a modified analogue of GHRP-6. It activates the growth hormone secretagogue receptor, now commonly known as the ghrelin receptor, and has been studied directly in humans for its acute effects on growth-hormone secretion.
What is Hexarelin?
Hexarelin is a synthetic hexapeptide belonging to the growth hormone-releasing peptide family.
It was developed as a structural analogue of GHRP-6 and contains several non-natural structural features intended to produce potent and reproducible biological activity.
The peptide acts primarily as an agonist of the growth hormone secretagogue receptor type 1a , or GHS-R1a.
This receptor is now more commonly known as the ghrelin receptor, because ghrelin was subsequently identified as its endogenous human ligand.
Hexarelin has been investigated directly in humans, where controlled studies demonstrated potent acute stimulation of growth-hormone secretion.
Scientific interest later expanded beyond endocrine research to include possible cardiovascular and tissue-level actions, although many of those findings remain experimental.
What does the name Hexarelin refer to?
Hexarelin is a six-amino-acid peptide, which is consistent with the hexa- portion of its name.
However, the scientific literature does not generally define “Hexarelin” as a formal acronym in the way that terms such as GHRP-6 are defined.
It is therefore more accurate to describe Hexarelin by its structural identity and pharmacological family rather than assign a literal expansion to every part of its name.
Hexarelin was developed from the GHRP-6 scaffold. A particularly important difference is the modified D-2-methyl-tryptophan residue.
The sequence also contains D-phenylalanine and an amidated C-terminus, distinguishing it from naturally occurring human peptide hormones.
A potent GHRP-6-derived secretagogue
Hexarelin emerged from medicinal-chemistry research seeking stronger synthetic growth hormone secretagogues with useful experimental pharmacology.
From synthetic GHRPs to the ghrelin system
Growth hormone-releasing peptides were discovered before researchers knew the identity of the natural hormone system through which they acted.
Early synthetic peptides demonstrated that growth hormone could be stimulated through a pathway distinct from the classical growth hormone-releasing hormone receptor.
GHRP-6 became a key first-generation compound. Hexarelin was subsequently developed as a modified analogue with strong GH-releasing activity.
By the 1990s, controlled human studies demonstrated that Hexarelin could produce a rapid and reproducible growth-hormone response.
Research on these synthetic compounds contributed to the discovery of the growth hormone secretagogue receptor.
In 1999, the endogenous ligand for that receptor was identified and named ghrelin, revealing the physiological hormone system that GHRPs had been pharmacologically activating.
Amino-acid structure
Hexarelin contains six residues and includes synthetic stereochemical and structural modifications designed during growth hormone secretagogue development.
Why are researchers interested in Hexarelin?
Hexarelin became valuable as an experimental endocrine tool because of its strong growth hormone-releasing activity and its interaction with the ghrelin receptor system.
Growth Hormone Release
Controlled human experiments demonstrate strong acute stimulation of circulating growth hormone.
Hypothalamic-Pituitary Biology
Hexarelin has helped researchers study the interaction of GHS signalling with GHRH, somatostatin and pituitary function.
Cardiovascular Research
Experimental work has investigated cardiac binding sites and possible actions beyond circulating growth hormone.
Endocrine Testing
The peptide has been investigated as a provocative stimulus for studying growth-hormone secretory capacity.
How does Hexarelin stimulate growth hormone?
Hexarelin activates the growth hormone secretagogue receptor and influences both hypothalamic and pituitary components of the GH axis.
GHS-R1a Activation
Hexarelin acts as an agonist of the growth hormone secretagogue receptor, which is also the receptor for ghrelin.
Hypothalamic Signalling
Human studies indicate that an intact hypothalamic pathway contributes strongly to the growth-hormone response.
Pituitary Somatotrophs
The secretagogue system ultimately stimulates pituitary somatotroph cells to release stored growth hormone.
GHRH Interaction
GHRH and Hexarelin can interact synergistically, producing larger GH responses than either signal in isolation.
Hexarelin research extends beyond the GH axis
Hexarelin attracted additional scientific interest when researchers observed cardiovascular actions that did not appear to be explained entirely by pituitary growth-hormone release.
Experimental work subsequently identified CD36, a multifunctional membrane glycoprotein, as a receptor associated with some cardiovascular actions of growth hormone-releasing peptides.
Small human studies also explored acute cardiac responses to Hexarelin in people with growth hormone deficiency and healthy controls.
These findings remain experimental. They do not establish that Hexarelin prevents, improves or treats heart disease in humans.
What potential applications have been investigated?
Hexarelin has mainly been used to investigate endocrine physiology. Broader therapeutic hypotheses remain substantially less established.
Growth Hormone Secretory Function
Hexarelin has been used experimentally to investigate pituitary GH reserve and the physiology governing pulsatile growth-hormone secretion.
Growth Hormone Deficiency Research
Human studies in people with GH deficiency examined whether Hexarelin responses could provide information about the level of hypothalamic or pituitary dysfunction.
Cardiac Signalling
Experimental research has investigated possible myocardial and vascular actions, including mechanisms involving CD36.
Ghrelin-Receptor Pharmacology
Hexarelin contributed to the wider development of synthetic growth hormone secretagogues and understanding of the ghrelin receptor system.
Evidence that Hexarelin changes hormone secretion or produces experimental cardiovascular effects does not establish a safe or effective long-term treatment for human disease.
How strong is the evidence?
Evidence for Hexarelin's acute endocrine activity is comparatively strong. Evidence for long-term therapeutic benefit is far less developed.
Molecular Pharmacology
Its membership of the GHRP/GHS-R signalling system is well characterized.
Human GH Response
Controlled human studies repeatedly demonstrate acute growth-hormone release.
Endocrine Mechanism
Human studies support both hypothalamic and pituitary involvement in its biological response.
Long-Term Therapy
Robust evidence establishing long-term clinical efficacy and safety is lacking.
What has been demonstrated in humans?
Hexarelin has been administered in controlled human endocrine research and produces strong acute GH responses.
Hexarelin has a substantially larger body of direct human pharmacology than many compounds currently described as research peptides.
In a double-blind, placebo-controlled dose-response study involving 12 healthy adult men, Hexarelin produced dose-dependent increases in circulating growth hormone.
Growth hormone concentrations peaked at approximately 30 minutes after intravenous administration in that experiment before declining towards baseline.
Another study investigated intravenous, subcutaneous, intranasal and oral administration in healthy volunteers. Growth-hormone responses were observed through multiple experimental routes, although biological availability differed.
Human research involving people with growth hormone deficiency also showed that the response to Hexarelin depended on the underlying hypothalamic-pituitary abnormality.
Acute studies also reported effects on hormones including prolactin, ACTH and cortisol under some experimental conditions.
These studies demonstrate pharmacological activity. They do not demonstrate that Hexarelin is an effective treatment for muscle gain, recovery, body-fat reduction, anti-ageing or other commonly promoted non-approved uses.
Where is Hexarelin in the development process?
Hexarelin progressed well beyond basic laboratory research and was administered in multiple human studies. However, it did not become a generally approved therapeutic medicine.
Human-studied investigational secretagogue
Hexarelin has substantial direct human pharmacodynamic evidence, particularly for acute growth-hormone secretion, but it should not be confused with an approved growth hormone therapy.
What don't we know?
Factors affecting Hexarelin stability
Hexarelin contains synthetic structural modifications including D-amino-acid residues. Storage and solution stability should nevertheless be based on analytical data for the exact material, counter-ion and formulation under investigation.
Temperature
Elevated temperature can accelerate chemical degradation of peptide research material.
Moisture
Humidity and moisture exposure can affect physical and chemical stability of lyophilized peptide material.
Solution Conditions
pH, buffer composition, solvent, concentration and ionic environment can influence peptide stability.
Material Specification
Purity, salt or counter-ion form, formulation and analytical identity should be defined for the material being studied.
Human-studied investigational growth hormone secretagogue
Hexarelin has been administered in controlled human research and has a well-documented ability to stimulate acute growth-hormone secretion.
Its experimental history also includes studies of hypothalamic-pituitary physiology, additional endocrine effects and possible cardiovascular mechanisms.
These findings do not establish Hexarelin as an approved treatment for growth hormone deficiency, muscle development, fat loss, recovery, ageing, cardiovascular disease or any other medical condition.
ASA Research Labs presents this information for scientific and educational purposes only. Nothing on this page should be interpreted as medical advice, dosing guidance or a recommendation for human use.
Selected scientific references
Selected peer-reviewed studies covering Hexarelin's molecular pharmacology, endocrine effects, human research and experimental cardiovascular biology.
Scientific research information only
This profile is provided for scientific and educational information. Hexarelin has been administered in controlled human endocrine studies, but it is not presented by ASA Research Labs as an approved treatment for growth hormone deficiency, muscle growth, recovery, body composition, ageing, cardiovascular disease or any other medical condition. Discussion of acute hormone responses, experimental cardiovascular findings or potential applications does not establish long-term safety or therapeutic efficacy. This page does not provide instructions for administration, dosing or human use.